Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

Architecture Research Office (ARO), in collaboration with Nelson Byrd Woltz Landscape Architects (NBW), completed the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

British royal family news divulges that Meghan Markle is in a jam following a five-year string of failures, the latest being her American Riviera Orchard fruit preserves.Instead of ARO, Meghan is now ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi ...

The examination is scheduled for February 24, 25, 27, 28, March 3, 4, 5, and 6, 2025. Here is all you need to know.